阿米卡星或卷曲霉素6至12个月治疗耐多药肺结核疗效观察  

Clinical observation on curative effect of amikacin or capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis for 6-12 months

作　　者：缪昌东 张德坤[1] 姜继军[2] 韩美芳[2] 

机构地区：[1]泰州市疾病预防控制中心,江苏泰州225300 [2]泰州市人民医院,江苏泰州225300

出　　处：《临床肺科杂志》2015年第11期1957-1959,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的：探讨注射阿米卡星和卷曲霉素治疗耐多药肺结核的远近期疗效。方法对2009年1月~2014年6月收治的耐多药肺结核病例治疗方案、不良反应、远近期疗效进行分析。结果51例耐多药肺结核患者中,44例完成6~12个月注射期治疗,治疗6个月末、12个月末、24个月末痰菌阴转率分别为58．82%、52．17%、48．48%；阿米卡星组不良反应较少,疗效较好。结论注射阿米卡星或卷曲霉素6~12个月治疗耐多药肺结核方案可行,加强不良反应的监测和及时处置,可避免严重不良反应的发生。Objective To investigate the curative effect of amikacin or capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis for 6-12 months. Methods We monitored and analyzed the treatment, adverse reactions, short and long term curative effect of multi-drug resistant pulmonary tuberculosis from January 2009 to June 2014. Results In all 51 patients with multi-drug resistant pulmonary tuberculosis, 44 cases completed 6-12 months′ injection, and the sputum negative conversion rate was 58. 82%, 52. 17% and 48. 48% respectively at the end of 6, 12 and 24 months. The amikacin group had less adverse reactions and better curative effect than the capreo-mycin group did. Conclusion Amikacin or capreomycin injection for 6-12 months is effective for multi-drug resistant tuberculosis, and the occurrence of serious adverse reactions can be avoided by monitoring of adverse reactions and timely disposal.

关 键 词：耐多药肺结核 阿米卡星 卷曲霉素 

分 类 号：R521[医药卫生—内科学]